

## Putting NICE guidance into practice

# **Costing statement: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326)**

Published: November 2014

The commissioner for this technology is NHS England.

The number of new people eligible for treatment with imatinib is around 170 per year for the population of England. Treatment is for a period of up to 3 years. The cost impact for treating these people is estimated to be approximately £2.8 million for year 1, £1.5 million for year 2 and £0.8m for year 3. The cumulative cost impact is therefore £2.8 million in year 1, £4.3 million in year 2 and £5.1 million from year 3 onwards.